Introduced:
Jun 25, 2025
Policy Area:
Health
Congress.gov:
Bill Statistics
3
Actions
15
Cosponsors
0
Summaries
1
Subjects
1
Text Versions
Yes
Full Text
AI Summary
AI Summary
No AI Summary Available
Click the button above to generate an AI-powered summary of this bill using Claude.
The summary will analyze the bill's key provisions, impact, and implementation details.
Error generating summary
Latest Action
Jun 25, 2025
Referred to the House Committee on Energy and Commerce.
Actions (3)
Referred to the House Committee on Energy and Commerce.
Type: IntroReferral
| Source: House floor actions
| Code: H11100
Jun 25, 2025
Introduced in House
Type: IntroReferral
| Source: Library of Congress
| Code: Intro-H
Jun 25, 2025
Introduced in House
Type: IntroReferral
| Source: Library of Congress
| Code: 1000
Jun 25, 2025
Subjects (1)
Health
(Policy Area)
Cosponsors (14 of 15)
(R-CA)
Oct 21, 2025
Oct 21, 2025
(R-SC)
Sep 23, 2025
Sep 23, 2025
(R-AZ)
Sep 10, 2025
Sep 10, 2025
(R-NC)
Sep 10, 2025
Sep 10, 2025
(R-CA)
Jun 25, 2025
Jun 25, 2025
(D-NC)
Jun 25, 2025
Jun 25, 2025
(R-LA)
Jun 25, 2025
Jun 25, 2025
(D-CA)
Jun 25, 2025
Jun 25, 2025
(D-NC)
Jun 25, 2025
Jun 25, 2025
(D-IL)
Jun 25, 2025
Jun 25, 2025
(D-NJ)
Jun 25, 2025
Jun 25, 2025
(D-NY)
Jun 25, 2025
Jun 25, 2025
(R-CA)
Jun 25, 2025
Jun 25, 2025
(R-AR)
Jun 25, 2025
Jun 25, 2025
Showing latest 14 cosponsors
Full Bill Text
Length: 3,589 characters
Version: Introduced in House
Version Date: Jun 25, 2025
Last Updated: Nov 15, 2025 2:10 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4132 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. R. 4132
To provide for digital communication of prescribing information for
drugs (including biological products), and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 25, 2025
Mrs. Harshbarger (for herself, Ms. Sherrill, Mr. Valadao, Mr. Davis of
North Carolina, Mr. Calvert, Ms. Ross, Ms. Letlow, Mr. Peters, Mr.
Schneider, Mr. Womack, and Mr. Tonko) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To provide for digital communication of prescribing information for
drugs (including biological products), and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
[From the U.S. Government Publishing Office]
[H.R. 4132 Introduced in House
(IH) ]
<DOC>
119th CONGRESS
1st Session
H. R. 4132
To provide for digital communication of prescribing information for
drugs (including biological products), and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 25, 2025
Mrs. Harshbarger (for herself, Ms. Sherrill, Mr. Valadao, Mr. Davis of
North Carolina, Mr. Calvert, Ms. Ross, Ms. Letlow, Mr. Peters, Mr.
Schneider, Mr. Womack, and Mr. Tonko) introduced the following bill;
which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To provide for digital communication of prescribing information for
drugs (including biological products), and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1.
This Act may be cited as the ``Prescription Information
Modernization Act of 2025''.
SEC. 2.
FOR DRUGS (INCLUDING BIOLOGICAL PRODUCTS).
(a) In General.--
(a) In General.--
Section 502
(f) of the Federal Food, Drug, and
Cosmetic Act (21 U.
(f) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 352
(f) ) is amended by adding at the end the
following: ``Required prescribing information for drugs subject to
section 503
(b)
(1) may be made available solely by electronic means
provided that the labeling complies with all applicable requirements of
law, that the manufacturer affords prescribers and dispensers the
opportunity to elect to also continue to receive all such information
in paper form, or to request paper labeling on an as-needed basis, and
after such request, and that the manufacturer promptly provides the
requested information without additional cost.
(b)
(1) may be made available solely by electronic means
provided that the labeling complies with all applicable requirements of
law, that the manufacturer affords prescribers and dispensers the
opportunity to elect to also continue to receive all such information
in paper form, or to request paper labeling on an as-needed basis, and
after such request, and that the manufacturer promptly provides the
requested information without additional cost.''.
(b) Rulemaking.--
(1) In general.--Not later than 1 year after the date of
the enactment of this Act, the Secretary of Health and Human
Services shall issue final regulations to--
(A) implement the amendment made by subsection
(a) ;
and
(B) provide instructions on how health care
professionals can receive paper copies of prescribing
information directly from the manufacturer or
distributor if desired.
(2) Economic impacts.--The Secretary of Health and Human
Services shall design the regulations required by paragraph
(1) so as to minimize the adverse economic impacts of such
regulations on prescribers and dispensers.
(c) Public Workshop.--Not later than 2 years after the date of the
enactment of this Act, the Secretary of Health and Human Services,
acting through the Commissioner of Food and Drugs, shall hold a public
workshop with relevant stakeholders to discuss how to continue to
optimize the format, accessibility, and usability of prescribing
information.
(d) Effective Date.--The amendment made by subsection
(a) shall
apply with respect to drugs introduced or delivered for introduction
into interstate commerce on or after the sooner of--
(1) the date that is 2 years after the date of the
enactment of this Act; or
(2) the effective date of the final regulations promulgated
to implement such amendment.
(e)
=== Definition. ===
-In this section, the term ``drug'' has the meaning
given to such term in
section 201 of the Federal Food, Drug, and
Cosmetic Act (21 U.
Cosmetic Act (21 U.S.C. 321).
<all>
<all>